Newsfeeds Archive - Page 2 of 6

2 minute read

CureVac, GS Partner Release Data On Influenza Vaccine Study

April 4, 12:18 PM

CureVac reveals Phase 2 interim data for its seasonal influenza vaccine in collaboration with GSK. Results show broad antigen coverage with acceptable safety. Positive findings against influenza A strains prompt further optimization for influenza B strains.

BNTX

1 minute read

Why Biopharmaceutical Player CureVac Shares Are Rising Today

By Nabaparna Bhattacharya

January 5, 11:31 AM

CureVac N.V. (NASDAQ: CVAC) shares are trading higher on Friday.

CVAC

3 minute read

Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session

By Avi Kapoor

December 19, 2:34 PM

Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy program. Compugen shares jumped 204.1% to $2.22 on Tuesday.

AFRM

2 minute read

Why Is COVID-19 Vaccine Player CureVac Stock Plummeting Today?

By Vandana Singh

December 19, 11:31 AM

A German court has invalidated a patent central to CureVac N.V's (NASDAQ: CVAC) lawsuit against BioNTech SE (NASDAQ: BNTX) related to seeking fair compensation for infringement of a portfolio of

BNTX

1 minute read

Bluebird Bio, Vertex Energy And Other Big Stocks Moving Lower On Tuesday

By Avi Kapoor

December 19, 11:19 AM

U.S. stocks traded higher, with the Dow Jones index gaining around 150 points on Tuesday. Shares of bluebird bio, Inc. (NASDAQ: BLUE) shares fell sharply during Tuesday’s session after the company announced a proposed public offering of $150 million of common stock.

ARRY

2 minute read

CureVac Announces Decision Of German Federal Patent Court In Broad Patent Litigation With BioNTech SE

By Benzinga Newsdesk

December 19, 10:39 AM

Validity of CureVac patent EP 1 857 122 B1 denied by German Federal Patent Court after nullity action filed by BioNTech SEDecision does not affect ongoing litigation in Germany regarding seven other intellectual property

BNTX

2 minute read

Acuitas Challenges CureVac in Legal Tussle Over COVID-19 Vaccine Technology

By Vandana Singh

November 15, 9:15 AM

Biotech company Acuitas Therapeutics has filed a lawsuit in Virginia federal court against Germany-based CureVac SE (NASDAQ: CVAC), accusing it of failing to credit Acuitas on patents related to COVID-19 vaccines.

BNTX

12 minute read

Earnings

Earnings Scheduled For November 14, 2023

By Benzinga Insights

November 14, 9:23 AM

Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue of $18.00 million.

ACXP

2 minute read

CureVac Announces Solid Progress In Phase 2 COVID-19 And Seasonal Flu Clinical Development Programs In Collaboration With GSK

By Benzinga Newsdesk

November 1, 8:27 AM

COVID-19 Phase 2 clinical trial fully enrolledStudy compares mono- and bivalent vaccine candidates against licensed comparator COVID-19 vaccineFirst participant dosed in seasonal flu Phase 2 part of combined Phase 1/2

CVAC

24 minute read

Options

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

September 28, 2:32 PM

During Thursday's session, 406 companies made new 52-week lows.

AAP